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Objective: To determine baseline clinical and ultrasonographic plaque factors predictive of progression or regression of
asymptomatic carotid stenosis and the predictive value of changes in stenosis severity on risk of ﬁrst ipsilateral cerebral or
retinal ischemic events (including stroke).
Methods: A total of 1121 patients with asymptomatic carotid stenosis of 50% to 99% in relation to the bulb diameter
(European Carotid Surgery Trial [ECST] method) underwent six monthly clinical assessments and carotid duplexes for
up to 8 years (mean follow-up, 4 years). Progression or regression was considered present if there was a change of at least
one grade higher or lower, respectively, persisting for at least two consecutive examinations.
Results: Regression occurred in 43 (3.8%), no change in 856 (76.4%), and progression in 222 (19.8%) patients. Younger
age, high grades of stenosis, absence of discrete white areas in the plaque, and taking lipid lowering therapy were inde-
pendent baseline predictors of increased incidence of regression. High serum creatinine, male gender, not taking lipid
lowering therapy, low grades of stenosis, and increased plaque area were independent baseline predictors of progression.
One hundred and thirty ﬁrst ipsilateral cerebral or retinal ischemic events, including 59 strokes, occurred. Forty (67.8%)
of the strokes occurred in patients whose stenosis was unchanged, 19 (32.2%) in those with progression, and zero in those
with regression. For the entire cohort, the 8-year cumulative ipsilateral cerebral ischemic stroke ratewas zero in patientswith
regression, 9% if the stenosis was unchanged, and 16% if there was progression (average annual stroke rates of 0%, 1.1%, and
2.0%, respectively; log-rank, P[ .05; relative risk in patients with progression, 1.92; 95% conﬁdence interval, 1.14-3.25).
For patients with baseline stenosis 70% to 99% in relation to the distal internal carotid (North American Symptomatic
Carotid Endarterectomy Trial [NASCET] method), in the absence of progression (n[ 349), the 8-year cumulative ipsi-
lateral cerebral ischemic stroke rate was 12%. In the presence of progression (n[ 77), it was 21% (average annual stroke rates
of 1.5% and 2.6%, respectively; log-rank, P[ .34). Only nine (30%) of the 30 strokes occurred in the progression group.
Conclusions: Progressive asymptomatic carotid stenosis identiﬁed a subgroup with about twice the risk of ipsilateral stroke
compared with those without progression. However, the clinical value of screening for progression simply for selecting
patients for carotid procedures is limited because of the low frequency of progression and its relatively low associated
stroke rate. The cost effectiveness of screening for change in stenosis severity to better direct current optimal medical
treatment needs testing. (J Vasc Surg 2014;59:956-67.)Anumberofnatural history studies inpatientswithasymp-
tomatic carotid stenosis have investigated the association
between stenosis progression and risk of ipsilateral cerebrovas-
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Table I. Duplex velocity criteria used in the Asymptomatic Carotid Stenosis and Risk of Stroke (ACSRS) study16
Angiographic diameter stenosis Duplex velocity criteria
N % E % PSVIC
18,19 EDVIC
18-20 PSVIC/PSVCC
21-23 PSVIC/EDVCC
24,25 EDVIC/EDVCC
11 50 <120 <40 <1.5 <7
30 60 <2.6
47 70 120-150 40-80 1.5-2 7-10
60 77 80-130 2-3.2
65 80 150-250
70 83 >130 3.2-4 10-20 2.6-5.5
82 90 >250 >4 20-30
90 94 >30 >5.5
95 99 Trickle ﬂow
CC, Common carotid; E, European Carotid Surgery Trial; EDV, end-diastolic velocity; IC, internal carotid; N, North American Symptomatic Carotid
Endarterectomy Trial; PSV, peak systolic velocity.
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(ACSRS) Study was a prospective international cohort
study. The primary objective13,14 was to assess the cerebro-
vascular risk stratiﬁcation potential of combinations of
patients’ baseline clinical and biochemical characteristics,
ultrasound-determined degree of stenosis, and plaque
morphology. Particularly important were history of contra-
lateral transient ischemic attack or stroke, stenosis severity
at baseline, and plaque texture features (grayscale median
[GSM], size of plaque area, size of juxtaluminal black
area, and presence of discrete white areas [DWAs]), which
could stratify stroke risk from less than 1% per year to more
than 10% per year.13,14
A secondary objective of the ACSRS study was to assess
the stroke risk stratiﬁcation value of stenosis progression or
regression using serial (6-monthly) duplex scanning. The
aims of the present report were to determine:
1) The incidence of stenosis progression (with or
without progression to occlusion) and regression;
2) the association of baseline clinical, biochemical, and
plaque features predictive of stenosis progression or
regression;
3) the predictive value of changes in the severity of
stenosis in terms of ipsilateral cerebral or retinal
ischemic (CORI) events including stroke. Associated
with this aim, we determined if stenosis progression is
a predictor of cerebrovascular events, is indepen-
dent of baseline stenosis, and investigated any addi-
tional predictive value of change in stenosis severity
compared with our previously published “ACSRS
BestBaselineRisk StratiﬁcationModel for Stroke.”13,14
METHODS
The methodology of the ACSRS study regarding inclu-
sion and exclusion criteria, recruitment sources, clinical and
biochemical characteristics, duplex examination, image
acquisition of plaques, image normalization and analysis,
and primary outcome measures and their use in strokerisk stratiﬁcation has been previously published.13-15 Only
the most relevant methodology is presented.
Patient recruitment
Inclusion and exclusion criteria. Newly referred
(<3 months) patients with 50% to 99% internal carotid
artery (ICA) stenosis in relation to the carotid bulb diam-
eter (European Carotid Surgery Trial [ECST] method)
without previous ipsilateral CORI events and without
neurological abnormality were recruited after written
informed consent. Patients who had had contralateral
CORI or vertebrobasilar symptoms or signs were included
if asymptomatic for at least 6 months prior to recruitment.
For patients with bilateral asymptomatic carotid atheroscle-
rosis, the side with the more severe stenosis was considered
ipsilateral. Patients who could not attend for a 6-monthly
neurological assessment and those with a limited life
expectancy because of conditions such as severe cardiac
failure or disseminated malignancy were excluded.
Baseline clinical and biochemical characteristics
At baseline, all patients had a history taken and a phys-
ical examination by the local neurologist, electrocardio-
graphic examination and collection of fasting blood for
determination of ﬁbrinogen, fasting lipids (total choles-
terol, high density lipoprotein cholesterol, low density lipo-
protein cholesterol, triglycerides), creatinine, and
hematocrit, as previously reported.13
Duplex examination
Bilateral carotid duplex scanning was performed on
admission to the study and every 6 months. Ultrasonogra-
phers from all centers were trained at the coordinating
center in grading internal carotid stenosis and plaque image
capture.13-15
Grading of internal carotid stenosis. Velocities were
obtained at the point of maximum stenosis in the ICA and
the center of the common carotid artery lumen. A combi-
nation of velocity measurements and velocity ratios was
Table II. The relationship between the incidence of regression, progression and occlusion in relation to baseline stenosis
class
Stenosis class Regression, No. (%) No change, No. (%) Progression, No. (%) Occlusion, No. (%) Total, No. (%)
50%-59% 0 61 (66) 30 (33) 1 (1.1) 92 (100)
60%-69% 3 (3.1) 59 (61) 34 (35) 1 (1.0) 97 (100)
70%-79% 9 (2.8) 262 (81) 50 (15) 1 (0.3) 322 (100)
80%-89% 16 (4.7) 252 (78) 45 (14) 8 (2.5) 321 (100)
90%-95% 15 (5.4) 214 (76) 31 (11) 20 (7.1) 280 (100)
95%-99% 0 8 (89) 0 1 (11) 9 (100)
Total 43 (3.8) 856 (76) 190 (17) 32 (2.9) 1121 (100)
c2: P ¼ .031 - <.001 <.001
c2: c2 for trend in comparison to the “No change” group.
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(internal carotid)/end diastolic velocity (common carotid)
e PSVic/EDVcc e ratio, as indicated by the “Joint
Recommendations for Reporting Carotid Ultrasound
Investigation in the United Kingdom,” allowing grading of
stenosis in deciles.25 In plaques that were not calciﬁed,
anatomical criteria using color ﬂow or power Doppler
imaging of the artery in transverse section (percent diam-
eter stenosis from measurements of vessel and residual
lumen diameter at the site of maximum stenosis) were used
to supplement velocity criteria.26-29 The degree of
contralateral ICA stenosis, if present, and contralateral
ICA occlusion were noted.
Progression and regression of stenosis. Using the
above criteria, stenoses were graded into six classes: 50%
to 59%, 60% to 69%, 70% to 79%, 80% to 89%, 90% to
95%, and 96% to 99% (ECST methodology). Progression
or regression was considered to occur if there was a change
in at least one class up or down respectively, provided it was
found on at least two consecutive visits, in order to mini-
mize any effect related to reproducibility issues. Occlusion
was also noted and included in the progression group,
unless otherwise stated. Only change in stenosis severity
detected prior to CORI events was used.
Outcome measures
The primary outcome measure was the ﬁrst ipsilateral
CORI event, including stroke (fatal or nonfatal).
Study exit points
Follow-up ceased with the ﬁrst occurrence of any of the
following: the ﬁrst primary outcome measure, carotid
endarterectomy/angioplasty or stenting for the still asymp-
tomatic study artery, death from causes other than ipsilat-
eral stroke, or loss to follow-up. Stroke, transient
ischemic attack, or death associated with carotid endarter-
ectomy/angioplasty or stenting for the still asymptomatic
study artery were not included in any of our analyses.
Statistical analysis
Initially, the relationship between the incidence of
regression, progression, and occlusion in relation to the
baseline severity of stenosis was determined. Subsequently,Kaplan-Meier curves were used to determine overall ipsilat-
eral stenosis progression, occlusion, and regression-free
survival. Hazard ratios for clinical, biochemical, and ultra-
sonic features for progression, occlusion, and regression
were determined using unadjusted Cox models. Kaplan-
Meier curves were also constructed for risk factors that
were signiﬁcant in the unadjusted models. Risk factors
that were signiﬁcant at P < .05 in these unadjusted models
for progression, occlusion, and regression were then
considered in multivariable Cox proportional hazards
models. The ability of each model to predict progression,
occlusion, or regression was tested by using the linear
predictor score (x*b) to construct receiver operating char-
acteristic (ROC) curves. Kaplan-Meier curves were used to
determine the ipsilateral CORI event and stroke rates in
relation to changes in ipsilateral stenosis.
The IBM SPSS version 20 (SPSS Inc, Chicago, Ill) was
used for statistical analysis.
RESULTS
The study included 1121 patients 39 to 89 years old
(mean age, 70.0 years; standard deviation, 7.7 years; 61%
men), recruited from 1998 to 2002, as previously re-
ported.13 Baseline characteristics have been previously re-
ported.13 During follow-up (range, 6 months-8 years;
mean, 4 years), 130 ﬁrst ipsilateral CORI events occurred
(59 strokes, of which 12 were fatal; 49 transient ischemic
attacks; and 22 amaurosis fugax episodes).
Incidence of stenosis progression, occlusion, and
regression
Among the 1121 patients, ipsilateral regression of
stenosis by one class or more occurred in 43 (3.8%). There
was no change in 856 (76.4%). Progression occurred in
222 (19.8%), of which progression without occlusion was
in 190 (16.9%) and progression to occlusion in 32
(2.9%). Progression by more than one class occurred in
26 (2.3%) patients. The incidence of regression, progres-
sion, and occlusion in relation to the stenosis at baseline
is shown in Table II.
The within-year incidence of progression was 4% in
year 1, 10% in year 2, 6% in years 3 and 4, 4% in year 5,
3% in year 6, 2% in year 7, and zero in year 8. The actuarial
Table III. Unadjusted hazard ratios (HRs) of risk factors for ipsilateral stenosis progression with or without occlusion,
occlusion, and regression
Risk factor
Progression
HR 95% CI P
Occlusion
HR 95% CI P
Regression
HR 95% CI P
Age (10-year increase) 1.19 1.01-1.41 .044 1.18 0.76-1.84 .452 0.62 0.44-0.87 .006
BMI (5 units increase) 1.03 0.82-1.15 .712 0.85 0.53-1.35 .486 1.15 0.81-1.63 .424
SBP (10 units increase) 1.08 0.99-1.16 .051 1.01 0.90-1.33 .351 1.00 0.85-1.19 .968
DBP (10 units increase) 1.07 0.93-1.22 .353 1.26 0.88-1.80 .214 1.37 0.99-1.88 .055
Creatinine (20% increase) 1.22 1.13-1.32 <.001 1.27 1.05-1.53 .013 0.89 0.69-1.15 .386
Ln (GSMD40) 0.78 0.51-1.20 .258 0.24 0.07-0.76 .015 0.74 0.28-1.96 .543
GSM <23 1.21 0.93-1.59 .157 2.62 1.29-5.30 .008 1.01 0.52-1.95 .972
Plaque area1/3 (mm2) 1.37 1.14-1.65 .001 1.46 0.90-2.38 .125 0.82 0.53-1.26 .366
Fibrinogen 1.01 0.87-1.18 .890 1.19 0.82-1.72 .362 1.08 0.75-1.55 .669
Total cholesterol 1.05 0.93-1.18 .419 1.12 0.83-1.50 .463 1.21 0.95-1.56 .124
LDL cholesterol 1.05 0.92-1.20 .436 1.06 0.76-1.50 .721 1.29 0.82-1.45 .572
HDL cholesterol 0.74 0.52-1.05 .095 0.88 0.37-2.89 .770 1.49 0.85-2.64 .164
Triglycerides 1.03 0.90-1.17 .683 0.93 0.62-1.39 .711 1.11 0.84-1.47 .470
Ipsilateral stenosis (10% increase) 0.84 0.76-0.93 .001 2.58 1.69-3.93 <.001 1.47 1.11-1.96 .009
Contralateral stenosis (10% increase) 1.05 0.95-1.16 .341 1.39 1.11-1.74 .004 1.06 0.91-1.23 .440
Plaque type 4þ5 1 1 1
3 1.16 0.77-1.75 .470 1.12 0.32-4.30 .798 0.95 0.40-2.26 .922
2 1.32 0.87-2.03 .195 2.58 0.74-8.97 .137 0.60 0.22-1.65 .322
1 1.57 0.89-2.76 .120 3.93 0.94-16.4 .061 2.36 0.82-6.73 .109
Male 1.71 1.28-2.28 .001 3.18 1.31-7.74 .011 1.56 0.81-3.01 .179
Smoking 0.91 0.64-1.28 .598 0.79 0.30-2.05 .631 1.34 0.66-2.73 .416
Coronary artery disease 1.36 1.04-1.78 .023 1.73 0.87-3.48 .120 1.14 0.60-2.14 .699
Atrial ﬁbrillation 1.20 0.53-2.71 .656 1.36 0.18-10.0 .760 2.44 0.68-10.1 .219
Hypertension 0.86 0.66-1.13 .292 1.21 0.57-2.55 .622 0.61 0.33-1.13 .119
Diabetes 1.23 0.89-1.69 .201 0.61 0.22-1.76 .364 0.68 0.26-1.72 .412
History of contr. TIA or stroke 1.26 0.92-1.72 .146 1.63 0.76-3.53 .211 0.31 0.07-1.29 .109
Antihypertensive therapy 0.87 0.67-1.14 .324 1.02 0.50-2.08 .959 0.74 0.40-1.36 .329
Antiplatelet therapy 0.87 0.60-1.27 .481 1.72 0.52-5.64 .373 0.99 0.39-2.54 .992
Lipid lowering therapy 0.66 0.48-0.91 .011 0.74 0.32-1.73 .494 2.52 1.38-4.02 .003
Contr. carotid occlusion 0.93 0.57-1.52 .774 2.07 0.80-5.36 .136 1.89 0.66-4.32 .269
Presence of DWA (>1) 1.22 0.92-1.63 .165 1.19 0.56-2.52 .642 0.52 0.29-0.96 .037
BMI, Body mass index; CI, conﬁdence interval; DBP, diastolic blood pressure; DWA, discrete white area; GSM, grayscale median; HDL, high density
lipoprotein; LDL, low density lipoprotein; SBP, systolic blood pressure; TIA, transient ischemic attack.
Skewed continuous predictors were transformed to be approximately symmetrically distributed. Signiﬁcant risk factors are in bold.
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94%, respectively.
Baseline predictors of stenosis progression, occlusion,
and regression
Hazard ratios for each individual baseline clinical,
biochemical, and ultrasonic risk factors associated with ipsi-
lateral progression of stenosis (with or without occlusion),
progression to occlusion, and regression are shown in
Table III.
Features associated with progression. Increasing
age, male gender, presence of coronary artery disease,
elevated plasma creatinine, and increasing plaque area
were signiﬁcant risk factors associated with increased inci-
dence of progression. Systolic blood pressure had a border-
line signiﬁcance (P ¼ .051). Increasing severity of baseline
ipsilateral stenosis and use of lipid lowering therapy were
signiﬁcant risk factors associated with a decreased incidence
of progression (Table III).
In a multivariable Cox proportional hazards model
(model 1) with the signiﬁcant features from Table III as
covariates, only male gender, elevated creatinine, not takinglipid lowering therapy, decreasing severity of baseline ipsilat-
eral stenosis, and increasing plaque area were independent
predictors of progression (Table IV). On the basis of the
model (model 1) shown in Table IV, the linear predictor
scores xb of the model were calculated for each patient.
The ROC curve constructed had an area under the curve
of 0.637 (95% conﬁdence interval [CI], 0.596-0.677).
The cumulative ipsilateral stenosis progression free
Kaplan-Meier curves for each of the independent predic-
tors in the Cox model 1 are shown in Fig 1, A-E.
Features associated with occlusion. Male gender,
elevated creatinine, increasing baseline ipsilateral stenosis
severity, increasing baseline contralateral stenosis severity,
and low GSM were signiﬁcant univariate predictors associ-
ated with increased incidence of occlusion (Table III).
In a multivariable Cox proportional hazards model
(model 2) with the signiﬁcant features from Table III as
covariates, only male gender, low GSM, and increasing
severity of baseline ipsilateral and contralateral stenosis
were independent predictors of occlusion (Table IV). On
the basis of this model (model 2) shown in Table IV, the
linear predictor scores xb of the model were calculated
Table IV. Proportional hazards models including
signiﬁcant variables from Table III with ipsilateral stenosis
progression (model 1) and occlusion (model 2) as the
dependent variable
Variable b HR 95% CI P
Model 1: Progression of stenosis as the dependent variable
Creatinine (20% increase) .191 1.210 1.114-1.315 <.001
Ipsilateral stenosis
(10% increase)
.193 0.824 0.742-0.916 <.001
Plaque area 1/3 (mm2) .280 1.323 1.095-1.599 .004
Male gender .357 1.429 1.067-1.914 .017
Lipid lowering therapy .375 0.687 0.498-0.948 .022
Model 2: Occlusion as the dependent variable
Log (GSMþ40) 1.296 0.274 0.084-0.894 .032
Ipsilateral stenosis
(10% increase)
.865 2.376 1.565-3.607 <.001
Contralateral stenosis
(10% increase)
.192 1.212 1.039-1.414 .014
Male gender 1.130 3.094 1.271-7.534 .013
Model 3: Regression as the dependent variable
Age (10-year increase) .450 0.638 0.450-0.904 .011
Ipsilateral stenosis
(10% increase)
.466 1.594 1.179-2.155 .002
Lipid-lowering therapy .820 2.272 1.232-4.189 .009
DWA .693 0.500 0.272-0.920 .026
CI, Conﬁdence interval; DWA, discrete white area; GSM, grayscale median;
HR, hazard ratio.
Covariates selected using backward elimination on all variables with 95% CI
not overlapping 1.
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under the curve of 0.793 (95% CI, 0.719-0.867).
The cumulative ipsilateral progression-to-occlusion
free Kaplan-Meier curves for each of the independent
predictors in the Cox model are shown in Fig 2, A-D.
Features associated with regression. Increasing age
and presence of DWAs were associated with a decreased
incidence of regression. Increasing severity of baseline ipsi-
lateral stenosis and use of lipid lowering therapy were asso-
ciated with increased incidence of regression (Table III).
In a multivariable Cox proportional hazards model
(model 3) with the signiﬁcant features from Table III as
covariates, younger age, use of lipid lowering therapy,
increasing severity of ipsilateral stenosis, and absence of
DWAs were independent predictors of regression
(Table IV). On the basis of this model (model 3) shown
in Table IV, the linear predictor scores xb of the model
were calculated for each patient. The ROC curve con-
structed had an area under the curve of 0.704 (95% CI,
0.620-0.788).
The cumulative ipsilateral regression free Kaplan-Meier
curves for each of the independent predictors in the Cox
model 3 are shown in Fig 3, A-D.
Change in stenosis severity and prediction of ipsilateral
CORI events, including stroke
Of the total of 130 ipsilateral CORI events, 88 (67.7%)
occurred in the patients whose stenosis was unchanged, 33
(25.4%) in those with progression without occlusion, nine(6.9%) in those that developed occlusion, and zero in those
with regression. The incidence of different CORI events in
patients with regression, no change, or progression
(including progression to occlusion) of stenosis is shown
in Table V. The CORI event-free rate in relation to
changes in stenosis is shown in Fig 4, A. Progression to
occlusion was associated with a higher CORI event rate
(9/32, 28%) compared with progression without occlusion
(33/190, 17%), but the difference was not statistically
signiﬁcant (c2, P ¼ .15).
Of the total of 59 ipsilateral ischemic strokes, 40
(67.8%) occurred in the patients whose stenosis was
unchanged, 15 (25.4%) in those with progression without
occlusion, four (6.8%) in those that developed occlusion,
and zero in those with regression. The ipsilateral stroke-
free rate in relation to changes in stenosis is shown in
Fig 4, B. Progression to occlusion was associated with
a higher stroke rate (4/32; 12.5%) compared with
progression without occlusion (15/190; 7.9%), but the
difference was not statistically signiﬁcant (Fisher exact
test, P ¼ .49).
For the entire cohort, the 8-year cumulative ipsilateral
ischemic stroke rate was zero in patients with regression,
9% if the stenosis was unchanged, and 16% if there was
progression (average annual stroke rate over 8 years of
0%, 1.1%, and 2.0%, respectively; log-rank, P ¼ .05).
Effect of baseline stenosis and progression on risk
of subsequent ipsilateral stroke. In the absence of
progression, the 8-year cumulative ipsilateral cerebral
ischemic stroke rate for patients with baseline stenosis in
relation to the bulb (ECST) of 50% to 69%, 70% to 89%,
and 90% to 99% was 4%, 8%, and 13%, respectively (average
annual stroke rate over 8 years of 0.5%, 1.0%, and 1.6%). In
the presence of progression, it was 8%, 15%, and 25%
(average annual stroke rate of 1.0%, 1.9%, and 3.1%).
For patients with baseline stenosis 70% to 99% in rela-
tion to the distal internal carotid (NASCET method;
n ¼ 449), in the absence of progression (n ¼ 349), the
8-year cumulative ipsilateral cerebral ischemic stroke rate
was 12%. In the presence of progression (n ¼ 77), it was
21% (average annual stroke rate over 8 years of 1.5% and
2.6%, respectively; log-rank, P ¼ .34). However, only
nine (30%) of the 30 strokes occurred in the progression
group.
For patients with baseline stenosis 80% to 99% (NAS-
CET method; n ¼ 325), in the absence of progression
(n ¼ 244), the 8-year cumulative ipsilateral cerebral
ischemic stroke rate was 14%. In the presence of progres-
sion (n ¼ 61), it was 25% (average annual stroke rate
over 8 years of 1.7% and 3.1%, respectively; log-rank,
P ¼ .31). However, only nine (36%) of the 25 strokes
occurred in the progression group.
In a multivariate Cox model with stroke as the depen-
dent variable and with baseline stenosis and progression of
stenosis as covariates, both covariates were signiﬁcant
(Table VI). When stenosis was used as the only covariate,
the area under the ROC curve of the model output was
0.580 (95% CI, 0.504-0.657). When progression was
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Fig 1. Effect of signiﬁcant factors in model 1 (Table IV) on progression free survival. A, Creatinine (log-rank, P <
.001). B, Ipsilateral stenosis (log-rank, P overall < .001). C, Plaque area (log-rank, P ¼ .004). D, Gender (log-rank,
P < .001). E, Lipid-lowering therapy (log-rank, P ¼ .009).
JOURNAL OF VASCULAR SURGERY
Volume 59, Number 4 Kakkos et al 961added to the model, the area under the ROC curve
increased to 0.629 (95% CI, 0.555-0.704; P > .05).
Contribution of progression in an established model of
stroke risk stratiﬁcation
In a multivariate model, developed from the same
cohort of patients13 that has been shown to be able to
predict the risk of stroke with an area under the ROC
curve of 0.80 (95% CI, 0.74-0.87) and stratify patients
according to the risk of stroke from 0.1% to 10% per
year, we added stenosis progression as a covariate.
Progression as a covariate was marginally signiﬁcant
(Table VII). Also, stenosis regression, when added as a co-
variate, was not signiﬁcant.
DISCUSSION
The results indicate that a number of factors are associ-
ated with plaque progression and regression. The 19.8%incidence of ipsilateral stenosis progression was close to
that found in previous studies with a similar duration of
follow-up.2,3,7,10 The annual incidence of progression was
high in the ﬁrst 3 years, decreasing gradually in subsequent
years. This suggests that there is a population of patients
with plaques that are likely to progress and a population
with plaques that in terms of stenosis are stable. Only
two previous studies have reported an annual incidence
of progression that was the same throughout the follow-
up period.4-7 Regression that occurred in 3.8% of patients
is also similar to what most previous studies have re-
ported,6,9,30-32 although a rate of 16% has been reported
in one study.33
Previous studies have demonstrated the association of
ipsilateral progression with age,1,11 hypertension,6,8,10
and coronary artery disease.5,7 However, this is the ﬁrst
time the incidence of progression is shown to be associated
with elevated creatinine, plaque area, and male gender.
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on lipid-lowering therapy, which is compatible with
a previous report of reduction in progression of carotid pla-
que area.34Elevated creatinine, low GSM indicating a hypoechoic
plaque, severe ipsilateral stenosis, contralateral stenosis, and
male gender were associated with progression to occlusion.
Previous studies have demonstrated the association
Table V. The incidence of ipsilateral cerebral or retinal ischemic (CORI) events in relation to changes in severity of
stenosis
Stenosis change No events, No. (%) Amaurosis fugax, No. (%) TIA, No. (%) Stroke, No. (%) Total, No. (%) All events, No. (%)
Regression 43 (100) 0 0 0 43 (100) 0
No change 768 (90) 16 (1.9) 32 (3.7) 40 (4.7) 856 (100) 88 (10)
Progression 180 (81) 6 (2.7) 17 (7.7) 19 (8.6) 222 (100) 42 (19)
Total 991 (88) 22 (2.0) 49 (4.4) 59 (5.3) 1121 (100) 130 (12)
RR - 1.52 2.15 1.92 - 1.93
95% CI - 0.60-3.84 1.22-3.80 1.14-3.25 - 1.38-2.71
CI, Conﬁdence interval; RR, relative risk; TIA, transient ischemic attack.
Progression in this table includes progression to occlusion. RR is the relative risk of events in patients with progression in relation to the rest of the patients.
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plaque,7 ipsilateral stenosis,5,6,11 or contralateral stenosis.6
However, this is the ﬁrst time the incidence of progression
to occlusion has been shown to be associated with elevated
creatinine and male gender. The prediction of progression
to occlusion using the signiﬁcant risk factors (GSM, ipsilat-
eral stenosis, contralateral stenosis, and male gender) in
a Cox proportional hazards model (model 2; Table IV)
was high as indicated by the area under the ROC curve
(0.793), and it may have a clinical application. Future
studies need to investigate whether in the presence of the
above risk factors patients should receive a more aggressive
risk factor modiﬁcation than what is proposed in current
guidelines.Increasing age and DWAs were associated with a low
incidence of regression. Increased age is often associated
with a higher incidence of plaque calciﬁcation and/or
higher collagen content and such plaques are unlikely to
remodel and regress. DWAs indicate the presence of pla-
ques that have neovascularization as shown by plaque
perfusion studies35 that may also be resistant to regression.
Lipid-lowering therapy was associated with increased inci-
dence of regression. The association between lipid-
lowering therapy and plaque regression in patients with
asymptomatic carotid stenosis has already been demon-
strated,36 and is a well-established action of statins, re-
ported to occur independently of the baseline cholesterol
levels.36 Our two observations on the reduced likelihood
Table VI. Proportional hazards model with stenosis and
progression as covariates and stroke as the dependent
variable
Variable b HR 95% CI P
Ipsilateral stenosis
(10% increase)
.295 1.343 1.068-1.687 .011
Progression .616 1.85 1.072-3.202 .027
CI, Conﬁdence interval; HR, hazard ratio.
Table VII. Progression of stenosis added as covariate in
a proportional hazards model of our previously published
report shown to predict the risk of future events
Variable b HR 95% CI P
Ipsilateral stenosis
(10% increase)
.017 1.017 1.002-1.032 .023
Log (GSM þ 40) 2.464 0.085 0.042-0.171 <.001
Plaque area1/3 (mm2) .63 1.878 1.463-2.413 <.001
DWA .725 2.065 1.292-3.302 .002
History of contralateral
TIA or stroke
.661 1.938 1.321-2.842 .001
Progression .353 1.424 0.980-2.067 .064
CI, Conﬁdence interval; DWA, discrete white area; GSM, grayscale median;
HR, hazard ratio; TIA, transient ischemic attack.
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patients on lipid-lowering therapy reiterate the signiﬁcant
role of reducing cholesterol levels in managing patients
with asymptomatic carotid artery disease. Additionally,
the ﬁnding that none of the patients with regression devel-
oped a stroke suggests that monitoring plaque changes
with ultrasound may be a surrogate endpoint for moni-
toring the effect of medical therapy.
The ipsilateral ischemic stroke-free survival at 8 years was
100% in the group of patients with regression, 91% in the
group without change in stenosis (average annual stroke
rate of 1.12%), and 84% in the group with progression of
stenosis (average annual stroke rate of 2.0%). Although
progression of stenosis identiﬁes a high-risk group, only 19
of all strokes occurred in this group. The remaining 40
strokes were in the group without change in stenosis.
Thus, although we have demonstrated that progression of
asymptomatic carotid stenosis can identify a subgroup with
about twice the risk of stroke compared with those without
progression, the clinical value of screening for progression
simply for selecting patients for carotid procedures is limited
because of the low frequency of progression and the
low number of predicted strokes. It appears that plaque
progression is a poor indicator of overall plaque instability.
This is supported further by the ﬁnding that progression
was not signiﬁcant when added to plaque texture features
previously shown to be able to stratify patients to an annual
risk of stroke from 1% to 10%.13
One of the most signiﬁcant ﬁndings in the ACSRS
study was the fact that none of the patients with regression
developed a stroke. A previous study has reported a low
neurological event rate in patients with plaque regression,30but no results on stroke were presented. Another study
has already demonstrated that in patients with plaque
regression, there was a 50% reduction on the incidence of
stroke at 5 years,34 an observation that explains the fall in
CORI event rates with medical therapy.37-40 Future studies
should test the efﬁcacy of modern medical interventions
such as low density lipoprotein reduction to a target of
70 mg/dL and blood pressure to a target of 130/
80 mm Hg in slowing down plaque progression or even
induction of regression and the associated stroke risk
reduction compared with surgical treatments.
A limitation of the study was that medical therapy was
left to the discretion of the physician in charge, and by
today’s standards, it was not optimal. Additionally, ipsilateral
carotid endarterectomy was performed in 129 patients
(11.5%) for a still asymptomatic study artery because the
clinician in charge or the patient requested it, as previously
reported,13 but it is unlikely that this would have introduced
signiﬁcant bias, given the small percentage of dropouts and
the fact that long-term follow-up was performed in most
cases. Also, the effect of changes in plaque characteristics
during follow-up on incident ipsilateral CORI event and
stroke rates, which might improve the otherwise marginal
contribution of stenosis progression, should be studied. An
advantage of our study was the use of contemporary grading
of carotid stenosis in deciles. The standard Strandness
groups of stenosis were developed at the time B-mode
imaging was very poor. However, during the last 15 years,
the use of transverse color ﬂow images and the PSVic/
EDVcc ratio as used in our study and now incorporated in
the guidelines25 allow accurate grading of stenosis in deciles.
CONCLUSIONS
Screening to detect progression of stenosis in patients
with asymptomatic carotid stenosis may marginally im-
prove the prediction of stroke risk based on stenosis alone,
but it is of relatively limited clinical value compared with
baseline stenosis severity combined with baseline plaque
image analysis and clinical features, which, as shown by
previous publications from the ACSRS cohort, can stratify
risk of annual stroke from less than 1% to 10%. Patients
with an annual stroke risk of less than 2% even when on
suboptimal medical therapy as in the ACSRS study should
not be entered into randomized controlled trials of medical
therapy vs surgery because on optimal medical therapy,
their risk may even be lower. They will be introducing
“noise” and weaken such studies. Only patients at higher
risk should be selected. Ideally, what is now needed is
that the ACSRS ﬁndings are conﬁrmed in a new cohort
on optimal medical therapy, and only those shown to be
at high risk despite optimal medical therapy should be
considered for randomization.
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at www.jvascsurg.org.DISCUSSIONDr John Ricotta (Washington, D.C.). You showed a remark-
able ability to discriminate between deciles of stenosis using ultra-
sound. It’s sometimes difﬁcult to do that using angiography. I
wonder how conﬁdent you are that you can discriminate between
a 70% to 80% stenosis and an 80% to 90% stenosis or a 60% to 70%
and a 70% to 80%. This would be a very unusual observation. I
realize you’re quite adept at this, but it’s certainly not something
we would expect in most labs.
Dr Stavros K. Kakkos.Well, this wasn’t the aim of the present
study, but it has been shown in the late ’90s, when these criteria
were published, that there was good correlation with angiography.
Dr Ricotta. But in this study did you correlate your ultra-
sound measurements with angiographic measurements? There
are also a whole series of studies using repeatability and variability
of angiographic measurements that suggests that there is about an
8% to 10% variation from one reader to another, and even inter-
reader variability is at the 10% range.
Dr Kakkos. I agree. However, all ultrasound scans were re-
ported centrally. The exam was reviewed carefully by experienced
readers and we used, as I said, combinations of velocities and
velocity ratios.
Dr Richard Cambria (Boston, Mass). Dr Kakkos, congratula-
tions on another ACSRS report. I followed this study in publica-
tions very carefully and used some of the material in an address
at this Society last year.
But I wonder a little bit about your conclusion. You showed at
the beginning, in your background slide, some of the prior data
that indicates that plaque progression is a risk factor, so I wonder
why your conclusion that says regression, which was a rare event in
your study, might be used to monitor or guide therapy. Shouldn’t
the conclusion be that the observation of progression should be an
important factor in clinical decision-making?
Our group has studied this issue of the control of carotid pla-
que, or lack thereof, with modern medical therapy. And as you
showed, a relatively small percentage of your patients were on
optimal medical therapy. In a paper to be published next month
in the Journal of Vascular Surgery, our data, even in patients
with what all would consider to be optimal medical therapy,
suggests that this medical therapy fails in a high percentage of
patients. So I wouldn’t want you to leave the audience with the
impression that modern medical therapy is going to be effective
in plaque regression.
Dr Kakkos. Unfortunately, progression was relatively rare.
And we know from previous studies that its positive predictive
value in predicting of future stroke is around 20%.
Additionally, progression wasn’t signiﬁcant in multivariate
analysis. So we have to be honest and objective when interpreting
our results. The only actual positive ﬁnding of our study was
regression, so this is why I report it that way.
Dr Ricotta. I don’t see anybody else up, so I guess I’m going
to get to ask one more question. You only saw regression in your
most severe stenosis; is that correct?Dr Kakkos. This is correct, yes.
Dr Ricotta. So would your recommendation for somebody
with a severe stenosis be to monitor them in the hopes that they
show regression, or would it be to operate on them because they
have the other characteristics that your study has shown are asso-
ciated with an increased stroke rate?
Dr Kakkos. Regression occurred more often in plaques that
were over 80% ECST, which is 60% NASCET, so it was moderate
to severe stenosis.
Dr Ricotta. But you didn’t get any regression in those
patients; you only got regression in the 80% and 90% group.
Dr Kakkos. No, that’s where regression was more frequent,
in patients with severe stenosis. Now, regarding the reason that
happened, to have at the same time occlusion and regression
both being more frequent, this might indicate the presence of an
unstable plaque that has not only the ability to progress to occlu-
sion but also to regress. That’s my interpretation of the ﬁndings.
Dr Pierre Karam (Montreal, Quebec, Canada). We would
like to leave with an idea about the degree of stenosis. You classi-
ﬁed stenosis very preciselye50, 60, 70, 80, 90. What are the
numbers that worry you? At what time do you worry that this
lesion is really severe and you should do something?
Dr Kakkos. We used peak systolic velocity and also peak
systolic intrastenotic velocity over the peak systolic velocity of
the common carotid; both are well-known criteria. Additionally,
we used the peak systolic velocity intrastenotic velocity over the
end-diastolic velocity of the common carotid artery. These are all
well-known criteria, and as I said, we used the combination for
criteria.
DrWilhelm Sandmann (Duisburg, Germany). Just a practical
remark. Several, several years ago when Dr Bonnet from London,
Ontario, tried to criticize the surgery on asymptomatic carotid
artery stenosis, a lot of studies were set up. And we had also one
in Dusseldorf under the leadership of Michael Henrich, who was
a very critical neurologist. And at that time, the caseload of carotid
endarterectomy was reduced by about 50% per year. But after the
study was over, the caseload was more than tripled. And the infor-
mation from the neurologists around Henrich was that all of them
were very glad that the trial was over because they were convinced
that the tight stenosis has to be taken away.
So I would take up the comment of Dr Ricotta and ask you,
do you think really that in a patient with a signiﬁcant or, as we
better say, critical carotid artery stenosis, the time has come to
propose medical treatment, or shouldn’t we do medical treatment
probably in the beginning with the plaque and when the patient is
at risk?
Dr Kakkos. As we have published twice, the main endpoint,
the purpose of the ACSRS, was to identify high-risk groups. And if
the risk is extremely high, the aim is to operate on. If you’re going
to replace surgery with best medical therapy, then we need
a randomized study. And CREST II, for sure, will try to answer
this question.
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